The Immunology of Atopic Dermatitis: Why Your Immune System Causes Eczema

What Is the Immunology Behind Atopic Dermatitis?

Atopic dermatitis (AD) is driven by a complex interaction between a defective skin barrier and an overactive immune system — specifically, an exaggerated type 2 (Th2) immune response. In healthy skin, the immune system and skin barrier work together to keep irritants and allergens out while maintaining a calm, non-inflamed state. In AD, both systems malfunction, creating a vicious cycle of barrier breakdown and inflammation.

The key immunological players are:

• Th2 cells: A subset of T-helper immune cells that are overactivated in AD. They produce the cytokines (signaling proteins) that drive eczema inflammation.
• IL-4 and IL-13: The master Th2 cytokines. They suppress skin barrier protein production (especially filaggrin), promote IgE production (driving allergic sensitization), and recruit inflammatory cells to the skin. These are the targets of dupilumab (Dupixent).
• IL-31: The "itch cytokine" — directly stimulates itch-sensing nerves in the skin. This is the target of nemolizumab, a newer anti-itch biologic.
• IL-5: Promotes eosinophil recruitment — eosinophils contribute to tissue damage and inflammation in AD skin.
• JAK-STAT signaling: An intracellular signaling pathway that amplifies Th2 cytokine signals. JAK inhibitors (baricitinib, upadacitinib, abrocitinib) block this pathway, offering a new treatment class for AD.

How the Immune Dysfunction Creates Eczema Symptoms

The vicious cycle:

1. Barrier defect: Genetic mutations (especially in the filaggrin gene, affecting ~30% of AD patients) create a leaky skin barrier that allows allergens, irritants, and microbes to penetrate.
2. Immune activation: The penetrating allergens activate dendritic cells in the skin, which stimulate Th2 cells to produce IL-4, IL-13, and other inflammatory cytokines.
3. Barrier worsening: IL-4 and IL-13 further suppress filaggrin and other barrier proteins — making the barrier even more defective. They also reduce antimicrobial peptide production, allowing Staphylococcus aureus to colonize eczema skin (found in over 90% of AD patients).
4. Itch-scratch cycle: IL-31 activates itch nerves. Scratching damages the barrier further. Damaged barrier allows more allergen penetration. More inflammation. More itch. The cycle perpetuates itself.

Why eczema is linked to asthma and allergies (the "atopic march"): The same Th2 immune overactivation that drives eczema also drives allergic rhinitis (hay fever), asthma, and food allergies. IL-4 promotes IgE class-switching — excess IgE is the hallmark of allergic disease. Many children with eczema progress to develop asthma and allergies as they grow older, a pattern called the "atopic march."

How Understanding Immunology Changes Treatment

Traditional treatments (address symptoms):

• Moisturizers repair the barrier temporarily but don't address immune dysfunction
• Topical corticosteroids suppress local inflammation broadly but don't target the specific Th2 pathway
• Calcineurin inhibitors (tacrolimus, pimecrolimus) block T-cell activation locally

Targeted biologic therapies (address root cause):

• Dupilumab (Dupixent): Blocks IL-4/IL-13 — the master drivers of Th2 inflammation. Addresses both inflammation and barrier dysfunction. FDA-approved for moderate-to-severe AD.
• Tralokinumab (Adbry): Blocks IL-13 specifically. FDA-approved for moderate-to-severe AD in adults.
• Nemolizumab: Blocks IL-31 (the itch cytokine). Targets itch directly at its immunological source. FDA-approved for prurigo nodularis; in development for AD.

JAK inhibitors (oral, target intracellular signaling):

• Upadacitinib (Rinvoq), abrocitinib (Cibinqo), baricitinib (Olumiant): Block JAK enzymes that amplify cytokine signals inside immune cells. Fast-acting oral pills. Very effective but require monitoring for side effects (infection risk, blood counts, lipids).
• Topical ruxolitinib (Opzelura): A topical JAK inhibitor — targets the JAK-STAT pathway directly in the skin. FDA-approved for mild-to-moderate AD.

When to See a Dermatologist

See a dermatologist if your eczema is moderate-to-severe and not controlled with over-the-counter moisturizers and mild topical steroids. Understanding the immunology of your eczema helps your dermatologist choose the most targeted treatment — if Th2 inflammation is the primary driver (as in most AD), biologic therapies or JAK inhibitors may provide transformative relief that broad-spectrum treatments couldn't achieve. A dermatologist can also help you understand how your eczema relates to any asthma or allergies you may have.

Frequently Asked Questions

Is eczema an autoimmune disease?

Eczema is classified as an immune-mediated (not autoimmune) disease. In autoimmune diseases (like lupus or pemphigus), the immune system attacks the body's own tissues directly. In eczema, the immune system overreacts to environmental triggers (allergens, irritants, microbes) rather than attacking self-tissue. The distinction matters because the treatment targets are different — eczema treatments focus on Th2 suppression rather than the broader immunosuppression used in autoimmune diseases.

Why does my eczema get worse with stress?

Stress hormones (cortisol, catecholamines) directly influence the immune system, promoting Th2 skewing — exactly the immune imbalance that drives eczema. Stress also increases IL-31 production (more itch), impairs skin barrier function, and triggers scratching behaviors. This is why eczema flares often coincide with emotional stress, and why stress management is a legitimate part of eczema treatment.

If my child has eczema, will they develop asthma?

Not necessarily, but the risk is elevated. About 30-50% of children with moderate-to-severe eczema develop asthma, and up to 75% develop allergic rhinitis. This progression (the "atopic march") is driven by the same Th2 immune dysfunction. Early, aggressive eczema treatment — particularly barrier repair and inflammation control — may help reduce this progression, though research is ongoing. Discuss prevention strategies with your pediatric dermatologist and allergist.

Are biologics safer than traditional immunosuppressants for eczema?

Generally, yes — biologics like dupilumab target specific immune pathways (IL-4/IL-13) rather than broadly suppressing the entire immune system. This means lower risk of serious infections, no organ toxicity (liver, kidney), and no need for regular blood monitoring. However, JAK inhibitors, while targeted, do carry some risks (infections, blood clots at higher doses) that require monitoring. Your dermatologist will weigh the risk-benefit ratio for your specific situation.

References

Trusted Resources

• National Eczema Association. nationaleczema.org
• American Academy of Dermatology Association. "Eczema." aad.org
• American Academy of Allergy, Asthma & Immunology. aaaai.org

Understanding why your immune system causes eczema opens the door to treatments that target the root cause — not just the symptoms. Talk to your dermatologist about targeted therapies.